Zofran Lawsuit Plaintiffs Look Ahead To Appointees For MDL Plaintiffs’ Steering Committee

January 04, 2016 – – ZofranLegal.com reports that plaintiffs involved in Zofran lawsuits consolidated in multidistrict litigation number 2657 are still awaiting an announcement regarding the appointees for the Plaintiffs’ Steering Committee. The Honorable Judge F. Dennis Saylor IV, who is overseeing the MDL lawsuits, noted on November 11th of 2015 that the Plaintiffs’ Steering Committee would be decided on at a later date.

The duties of the Plaintiff’s Steering Committee are to supervise the paralegals and volunteer attorneys as they review documents, prepare lawsuit briefs, record depositions, and investigate each common aspect of the many lawsuits involved in the MDL. Additionally, they will distribute important documents to plaintiffs and help attorneys for those plaintiffs so that they will be able to better focus on the similar versus the unique aspects of each individual case.

Lawsuits against Zofran all similarly allege that exposure to the drug while growing in the womb can cause fetuses to develop severe congenital birth defects. The number of parents stepping forward with these allegations and filing suit against Zofran manufacturer GlaxoSmithKline only continues to grow, and lawsuits currently number over 200. Some of the suits allege wrongful death, as the infants passed away due to the severity of their birth defects.

Defects most commonly linked to Zofran exposure by plaintiffs are cleft lip and palate, ventricular septal defect and atrial septal defect, transposition of the greater vessels, tetralogy of fallot, kidney and respiratory defects, and clubfoot.

Plaintiffs make special note of the fact that GlaxoSmithKline was never given FDA-approval to use Zofran to treat morning sickness in pregnant women, nor did they test for safety for this use. Despite this fact, the company chose to market the drug “off-label” to this consumer group, and to Ob/Gyns across the nation as well. Since this advertising campaign led the medical community to believe the drug was safe for use by expectant mothers, it has been widely prescribed “off-label” for this use.

Attorneys at Monheit Law are working to assist those who have given birth to children with defects after using Zofran while pregnant. These individuals may be entitled to compensation. Monheit Law is offering free Zofran consultations at this time.

To request more information on the ongoing Zofran litigation, contact Michael Monheit, lead attorney at Monheit Law, by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60006885